The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process.
http://www.biospace.com/news_story.aspx?StoryID=280637&full=1
http://www.biospace.com/news_story.aspx?StoryID=280637&full=1
No comments:
Post a Comment